{"id":56466,"date":"2023-05-02T23:04:46","date_gmt":"2023-05-02T21:04:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/"},"modified":"2023-05-02T23:04:46","modified_gmt":"2023-05-02T21:04:46","slug":"kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/","title":{"rendered":"Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting"},"content":{"rendered":"<div>\n<p>\n<i>Preclinical data demonstrate iGPS particles efficiently and specifically deliver CAR molecules to T cells in vivo for durable tumor clearance without need for lymphodepleting chemotherapy<\/i><\/p>\n<p>\n<i>Company developing iGPS technology to provide potentially safe, efficacious, <\/i><i>manufacturable, and widely accessible \u201coff-the-shelf\u201d in vivo CAR T therapies; discloses multiple myeloma as lead program<\/i><\/p>\n<p>\n<i>Company to share additional preclinical data during oral presentation highlighting potential of iGPS particles to generate CAR T cells clinically<\/i><\/p>\n<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, announced today that it will share initial preclinical data on its in vivo Gene Placement System (iGPS\u2122) technology during an oral presentation at the American Society of Gene &amp; Cell Therapy (ASGCT) 26<sup>th<\/sup> Annual Meeting, occurring May 16-20, 2023, in Los Angeles.<\/p>\n<p>\nThe preclinical data presented will demonstrate that Kelonia\u2019s iGPS technology uniquely enables safe and efficient in vivo generation of highly efficacious CAR T cells. In a humanized mouse model of multiple myeloma treatment, when an anti-BCMA CAR transgene was delivered directly in vivo using iGPS particles, low intravenous dose levels resulted in complete initial tumor regression comparable to ex vivo-manufactured CAR T cells. However, functional CAR T cell persistence after iGPS particle treatment resulted in significantly longer tumor control compared to ex vivo-generated CAR T cells. Despite efficient in vivo CAR gene transfer to T cells, no concerning or unexpected \u201coff-target\u201d transduction was observed including in vital, progenitor or reproductive organs.<\/p>\n<p>\n\u201cCAR T cells have been transformative for patients suffering from lethal cancers. But manufacturing unique CAR T cells for every patient has limited access to this incredible medicine. The preclinical data we\u2019ll present at ASGCT demonstrates the potential for potent, durable and safe CAR T cells generated by our iGPS in vivo delivery technology, without the requirement for preparative chemotherapy,\u201d said Kevin Friedman, Ph.D., Founder, President, and Chief Scientific Officer, Kelonia Therapeutics. \u201cThis is the first step toward our vision of solving the central challenge of genetic medicines: democratizing and enabling access when and where patients need them. We look forward to sharing detailed data at the conference.\u201d<\/p>\n<p>\nDetails for the oral presentation are as follows:<\/p>\n<p>\n<b>Abstract Title<\/b>: Potent in vivo transduction by iGPS particles generates CAR T cells with durable anti-tumor activity<\/p>\n<p>\n<b>Presenter<\/b>: Shannon Grande Contrastano, Ph.D., Senior Director, Preclinical Sciences, Kelonia Therapeutics<\/p>\n<p>\n<b>Session Date\/Time<\/b>: Wednesday, May 17, 2023: 3:45-5:30 PM PDT<\/p>\n<p>\n<b>Abstract number<\/b>: 90<\/p>\n<p>\n<b>About Kelonia Therapeutics<\/b><\/p>\n<p>\nKelonia is pioneering a new wave of genetic medicines using its in vivo gene placement system (iGPS<sup>\u2122<\/sup>). The company\u2019s simple and elegant cutting-edge in vivo gene delivery technology uses an advanced lentiviral vector particle harboring envelope modifications to improve in vivo gene transfer efficiency and tropism molecules to facilitate T-cell specific delivery. With an initial focus on developing transformational in vivo CAR T therapies for hematologic cancers, Kelonia is building a pipeline of genetic medicines for a range of diseases, with the bold goal of making genetic medicines accessible to every patient in need, when and where they need them. Learn more about Kelonia at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.keloniatx.com&amp;esheet=53391804&amp;newsitemid=20230502005932&amp;lan=en-US&amp;anchor=www.keloniatx.com&amp;index=1&amp;md5=036659ef95bda9a5313bc7ea811e8fe3\" rel=\"nofollow noopener\" shape=\"rect\">www.keloniatx.com<\/a> and follow us on LinkedIn and Twitter.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nAdam Silverstein<br \/>\n<br \/>Scient PR<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x61;&#100;a&#x6d;&#x40;&#115;c&#x69;&#101;n&#x74;&#x70;&#114;&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x61;&#100;a&#x6d;&#64;s&#x63;&#105;e&#x6e;&#x74;&#112;&#x72;&#x2e;&#99;o&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Preclinical data demonstrate iGPS particles efficiently and specifically deliver CAR molecules to T cells in vivo for durable tumor clearance without need for lymphodepleting chemotherapy Company developing iGPS technology to provide potentially safe, efficacious, manufacturable, and widely accessible \u201coff-the-shelf\u201d in vivo CAR T therapies; discloses multiple myeloma as lead program Company to share additional preclinical &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56466","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Preclinical data demonstrate iGPS particles efficiently and specifically deliver CAR molecules to T cells in vivo for durable tumor clearance without need for lymphodepleting chemotherapy Company developing iGPS technology to provide potentially safe, efficacious, manufacturable, and widely accessible \u201coff-the-shelf\u201d in vivo CAR T therapies; discloses multiple myeloma as lead program Company to share additional preclinical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-02T21:04:46+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting\",\"datePublished\":\"2023-05-02T21:04:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\\\/\"},\"wordCount\":539,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\\\/\",\"name\":\"Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-05-02T21:04:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting - Pharma Trend","og_description":"Preclinical data demonstrate iGPS particles efficiently and specifically deliver CAR molecules to T cells in vivo for durable tumor clearance without need for lymphodepleting chemotherapy Company developing iGPS technology to provide potentially safe, efficacious, manufacturable, and widely accessible \u201coff-the-shelf\u201d in vivo CAR T therapies; discloses multiple myeloma as lead program Company to share additional preclinical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-02T21:04:46+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting","datePublished":"2023-05-02T21:04:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/"},"wordCount":539,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/","name":"Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-05-02T21:04:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/kelonia-therapeutics-announces-upcoming-oral-presentation-of-preclinical-data-with-first-details-of-igps-technology-at-asgct-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Kelonia Therapeutics Announces Upcoming Oral Presentation of Preclinical Data with First Details of iGPS\u2122 Technology at ASGCT Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56466"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56466\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}